- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00351728
Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone
July 5, 2016 updated by: Jonsson Comprehensive Cancer Center
Patients diagnosed with ocular melanoma consent to participate in the study.
Combined PET/CT scans of the whole body are performed at baseline, three months later, and six months after that for a total of three combined scans in the first year.
Subsequently, these combined scans will be performed at 6-monthly intervals for a total of two combined scans per year.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
174
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095-7000
- Jules Stein Eye Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
choroidal melanoma patients
Description
Inclusion Criteria:
- Patients with a diagnosis of ocular melanoma (a pigmented malignant tumor) involving the choroid and/or ciliary body (the blood vessel layer in the back of the eye and/or the part of the eye behind the iris).
- Patients 18 years of age or older.
- Patients able to give informed consent.
Exclusion Criteria:
- Patients who refuse to participate in the study.
- Patients who are unable to cooperate with or cannot undergo PET/CT scanning.
- Patients who will be moving out of the area of UCLA during the ten years of this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Tara A McCannel, MD, PhD, Jules Stein Eye Institute, UCLA
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2006
Primary Completion (Actual)
August 1, 2012
Study Completion (Actual)
August 1, 2012
Study Registration Dates
First Submitted
July 12, 2006
First Submitted That Met QC Criteria
July 12, 2006
First Posted (Estimate)
July 13, 2006
Study Record Updates
Last Update Posted (Estimate)
July 7, 2016
Last Update Submitted That Met QC Criteria
July 5, 2016
Last Verified
July 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UCLA IRB #05-04-016
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ocular Melanoma
-
Delcath Systems Inc.Active, not recruitingMetastatic Uveal Melanoma | Metastatic Ocular MelanomaUnited States
-
National Cancer Institute (NCI)TerminatedMetastatic Uveal Melanoma | Metastatic Ocular MelanomaUnited States
-
Delcath Systems Inc.IQVIA BiotechCompletedMelanoma, OcularUnited States, Spain, Italy, Germany, United Kingdom, Switzerland, Belgium, Austria, France
-
National Cancer Institute (NCI)CompletedIris Melanoma | Stage IV Uveal Melanoma | Medium/Large Size Posterior Uveal Melanoma | Recurrent Uveal Melanoma | Ocular Melanoma With Extraocular Extension | Small Size Posterior Uveal MelanomaUnited States, Canada
-
H. Lee Moffitt Cancer Center and Research InstituteTurnstone Biologics, Corp.RecruitingMetastatic Melanoma | Conjunctival Melanoma | Ocular Melanoma | Unresectable Melanoma | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Iris Melanoma | Acral Melanoma | Non-Cutaneous MelanomaUnited States
-
MelanomaPRO, RussiaRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma, Stage II | Melanoma, Uveal | Melanoma in Situ | Melanoma, OcularRussian Federation
-
Aura BiosciencesCompletedOcular Melanoma | Uveal Melanoma | Choroidal MelanomaUnited States
-
Aura BiosciencesActive, not recruitingOcular Melanoma | Uveal Melanoma | Choroidal MelanomaUnited States
-
Craig L Slingluff, JrCelldex TherapeuticsActive, not recruitingMelanoma | Ocular Melanoma | Uveal MelanomaUnited States
-
Jonsson Comprehensive Cancer CenterCompleted